Stock Events

Stock Events

BioVaxys Technology 

0
0
+€0.00+0% 00:00 Today

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Financials

-Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
0Revenue
-2.62MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 5LB.MU. It's not an investment recommendation.
Amazon
3
AMZN
Apple
2
AAPL
Microsoft
2
MSFT
Tesla
2
TSLA

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Novavax
NVAX
Mkt Cap1.53B
Novavax is a competitor because it also focuses on developing vaccines for infectious diseases, similar to BioVaxys's focus on COVID-19 and cancer vaccines.
Moderna
MRNA
Mkt Cap55.09B
Moderna is a direct competitor in the mRNA vaccine space, particularly for COVID-19, competing with BioVaxys's vaccine development efforts.
BioNTech
BNTX
Mkt Cap25.64B
BioNTech competes in the development of vaccines for infectious diseases and cancer, directly overlapping with BioVaxys's areas of focus.
Pfizer
PFE
Mkt Cap159.36B
Pfizer, in collaboration with BioNTech, competes in the COVID-19 vaccine market, directly affecting BioVaxys's vaccine initiatives.
Johnson & Johnson
JNJ
Mkt Cap645.95B
Johnson & Johnson competes in the vaccine market with its own COVID-19 vaccine, posing competition to BioVaxys's development efforts.
Astrazeneca
AZN
Mkt Cap252.33B
AstraZeneca competes in the COVID-19 vaccine space, which is a key area of development for BioVaxys.
GSK
GSK
Mkt Cap101.78B
GlaxoSmithKline competes in the development of vaccines, including for infectious diseases, making it a competitor to BioVaxys.
Sanofi
SNY
Mkt Cap107.39B
Sanofi competes in the vaccine market, including efforts in developing COVID-19 vaccines, making it a competitor to BioVaxys.
Inovio Pharmaceuticals
INO
Mkt Cap133.38M
Inovio Pharmaceuticals competes in the development of DNA vaccines for infectious diseases and cancer, overlapping with BioVaxys's focus areas.

About

BIOVAXYS TECHNOLOGY CORP
Show more...
CEO
James Christopher Passin
Employees
3
Country
Canada
ISIN
CA09076M1014
WKN
000A41C58

Listings

CN
CA
BIOV.CN
STU
DE
5LB0.STU
MU
DE
5LB.MU
F
DE
5LB0.F

0 Comments

Share your thoughts

FAQ

What is BioVaxys Technology stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Boerse Muenchen exchange BioVaxys Technology stocks are traded under the ticker 5LB.MU.
What is BioVaxys Technology revenue for the last year?▼
BioVaxys Technology revenue for the last year amounts to 0 EUR.
What is BioVaxys Technology net income for the last year?▼
5LB.MU net income for the last year is -2.62M EUR.
How many employees does BioVaxys Technology have?▼
As of September 04, 2026, the company has 3 employees.
In which sector is BioVaxys Technology located?▼
BioVaxys Technology operates in the Health & Wellness sector.
When did BioVaxys Technology complete a stock split?▼
The last stock split for BioVaxys Technology was on September 11, 2025 with a ratio of 1:10.
Where is BioVaxys Technology headquartered?▼
BioVaxys Technology is headquartered in Etobicoke, Canada.